3.4.23.22 (1S)-2-(1H-indol-3-yl)-1-[5-(2,4,6-trimethylbenzyl)-1,3-thiazol-2-yl]ethanamine - 235402 3.4.23.22 (2R)-2-amino-N'-[(E)-(4-hydroxynaphthalen-1-yl)methylidene]-2-phenylacetohydrazide - 235436 3.4.23.22 (2S)-2-amino-2-[4-(trifluoromethyl)phenyl]-N'-[(E)-[3-(trifluoromethyl)phenyl]methylidene]acetohydrazide - 235475 3.4.23.22 (2S)-2-amino-2-[4-(trifluoromethyl)phenyl]-N'-[(E)-[4-(trifluoromethyl)phenyl]methylidene]acetohydrazide - 235476 3.4.23.22 (2S)-2-amino-3-(1H-indol-3-yl)-N'-[(E)-(2,4,6-trimethylphenyl)methylidene]propanehydrazide - 235477 3.4.23.22 (2S)-2-amino-3-(1H-indol-3-yl)-N'-[(E)-(2-methylphenyl)methylidene]propanehydrazide - 235478 3.4.23.22 (2S)-2-amino-3-(1H-indol-3-yl)-N'-[(E)-phenylmethylidene]propanehydrazide - 235479 3.4.23.22 (2S)-2-amino-3-(1H-indol-3-yl)-N'-[(E)-[3-(trifluoromethyl)phenyl]methylidene]propanehydrazide - 235480 3.4.23.22 (2S)-2-amino-3-(1H-indol-3-yl)-N'-[(E)-[4-(trifluoromethyl)phenyl]methylidene]propanehydrazide - 235481 3.4.23.22 (2S)-2-amino-N'-[(1E)-2-methylbutylidene]-2-[4-(trifluoromethyl)phenyl]acetohydrazide - 235482 3.4.23.22 (2S)-2-amino-N'-[(E)-(2,6-dimethylphenyl)methylidene]-3-(1H-indol-3-yl)propanehydrazide - 235483 3.4.23.22 (2S)-2-amino-N'-[(E)-(2-bromophenyl)methylidene]-3-(1H-indol-3-yl)propanehydrazide - 235484 3.4.23.22 (2S)-2-amino-N'-[(E)-(2-fluorophenyl)methylidene]-3-(1H-indol-3-yl)propanehydrazide - 235485 3.4.23.22 (2S)-2-amino-N'-[(E)-(2-hydroxy-3-methylphenyl)methylidene]-2-[4-(trifluoromethyl)phenyl]acetohydrazide - 235486 3.4.23.22 (2S)-2-amino-N'-[(E)-(2-hydroxy-3-methylphenyl)methylidene]-3-(1H-indol-3-yl)propanehydrazide - 235487 3.4.23.22 (2S)-2-amino-N'-[(E)-(3-methylphenyl)methylidene]-2-[4-(trifluoromethyl)phenyl]acetohydrazide - 235488 3.4.23.22 (2S)-2-amino-N'-[(E)-(pyridin-2-yl)methylidene]-2-[4-(trifluoromethyl)phenyl]acetohydrazide - 235489 3.4.23.22 (2S)-2-amino-N'-[(E)-cyclohexylmethylidene]-2-[4-(trifluoromethyl)phenyl]acetohydrazide - 235490 3.4.23.22 (S)-2-amino-2-(4-(trifluoromethyl)phenyl)acetohydrazide - 235741 3.4.23.22 (S)-2-amino-3-(1H-indol-3-yl)propanehydrazide - 235742 3.4.23.22 (S)-2-amino-N'-(cyclopentylmethylene)-2-(4-(trifluoromethyl)phenyl)acetohydrazide trifluoro acetic acid - 235743 3.4.23.22 (S)-2-amino-N'-benzylidene-2-(4-(trifluoromethyl)phenyl)acetohydrazide - 235744 3.4.23.22 1-(4-ethynylphenyl)piperazine - 235802 3.4.23.22 1-(4-[1-[2-(4-chlorophenyl)ethyl]-1H-1,2,3-triazol-4-yl]phenyl)piperazine - 235803 3.4.23.22 2,6-dimethylbenzaldehyde - 235947 3.4.23.22 2-(2,4,6-trimethylphenyl)ethyl L-tryptophanate - 235973 3.4.23.22 2-Bromobenzaldehyde - 5095 3.4.23.22 2-Fluorobenzaldehyde - 3776 3.4.23.22 2-hydroxy-3-methylbenzaldehyde - 236088 3.4.23.22 2-Methylbenzaldehyde - 3593 3.4.23.22 2-[1-[2-(2-fluorophenyl)ethyl]-1H-1,2,3-triazol-4-yl]-1-phenylethan-1-amine - 236111 3.4.23.22 3-(trifluoromethyl)benzaldehyde - 236155 3.4.23.22 4-(2-[4-[4-(piperazin-1-yl)phenyl]-1H-1,2,3-triazol-1-yl]ethyl)phenol - 236218 3.4.23.22 4-(trifluoromethyl)benzaldehyde - 48660 3.4.23.22 4-(trifluoromethyl)benzene-1-carboximidamide - 236223 3.4.23.22 benzaldehyde - 146 3.4.23.22 BW624 - 118055 3.4.23.22 CP-80,794 transition state analogue inhibitor 54361 3.4.23.22 D-Novo - 118054 3.4.23.22 H189 transition state analogue inhibitor 33799 3.4.23.22 H189 - 33799 3.4.23.22 H256 transition state analogue inhibitor 33800 3.4.23.22 H256 - 33800 3.4.23.22 H261 - 54360 3.4.23.22 L363564 statine-containing renin inhibitor, hydrogen bonding interaction witht the enzyme, e.g. via Asp32 and Asp215, overview 132569 3.4.23.22 additional information cysteine; HgCl2; iodoacetamide; NEM; not: sodium tetrathionate; PCMB; TLCK; TPCK 2 3.4.23.22 additional information a structural comparison of 21 inhibitor complexes of endothiapepsin; interaction of aspartic proteinases with naturally occuring inhibitors from actinomycetes and Ascaris lumbricoides 2 3.4.23.22 additional information molecular mechanism of enzyme inhibition by phosphinate and phosphonate inhibitors, molecular dynamic simulations for investigation of the hydrogen bonding pattern, structure, overview 2 3.4.23.22 N',N'''-((1E,1'E)-1,3-phenylenebis(methaneylylidene))bis(2-amino-3-(1H-indol-3-yl)propanehydrazide) - 236479 3.4.23.22 N-[2-(2,4,6-trimethylphenyl)ethyl]-L-tryptophanamide - 236891 3.4.23.22 Oligopeptide inhibitors PD125967 and PD125754 99519 3.4.23.22 PD-129,541 transition state analogue inhibitor 17271 3.4.23.22 PD-130,328 transition state analogue inhibitor 54362 3.4.23.22 PD-135,040 gem-diol inhibitor 118056 3.4.23.22 pepstatin - 396 3.4.23.22 pepstatin complex formation, structure analysis, conformation changes induced by protein-inhibitor association, proton release and uptake, overview 396 3.4.23.22 pepstatin A - 309 3.4.23.22 pepstatin A strong inhibition, the inhibitor motif -CH(OH)-CH2- mimicks the tetrahedral intermdiate of the catalytic reaction 309 3.4.23.22 rac-(2R,2'R)-N',N'''-((1E,1'E)-1,3-phenylenebis(methaneylylidene))bis(2-amino-3-phenylpropanehydrazide) - 237057 3.4.23.22 Synthetic human statine-containing renin inhibitor H-189 98763 3.4.23.22 Synthetic polypeptide inhibitor structure 98773 3.4.23.22 Synthetic renin inhibitor CP-69,799 46600 3.4.23.22 Transition-state isostere inhibitor of renin - 98359